Absolute blood pressure monitoring technology to be presented at the American Heart Association Hypertension Scientific Sessions
OKLAHOMA CITY, Sept. 4, 2025 /PRNewswire/ — Biozen, LLC a digital health innovator integrating advanced biosensors with proprietary algorithms, will present its cuffless blood pressure technology at the American Heart Association (AHA) Hypertension Scientific Sessions on Sept. 5 at 9:00 a.m. in Baltimore, Maryland (Poster Session 2, Poster #FR443).
The Biozen™ BP1000 device delivers absolute blood pressure measurement from the fingertip using the oscillometric method. This is the same validated standard as automated arm cuffs without the bulk or discomfort. The BP1000 incorporates the Biozen BP Sensor, a biosensor SiP (System in Package) that combines optical and pressure sensors. Biozen’s technology pairs its BP Sensor with proprietary algorithms, and in the future, will be incorporated into smartphones and wearables with cloud-based platforms. Together, these innovations enable users to conveniently check and securely share cuffless blood pressure readings anywhere.
“Hypertension affects 1.3 billion adults worldwide, and nearly half are unaware they have it,” said Dikran Tourian, CEO of Biozen. “We see Biozen not just as a device maker, but as a digital health technology that empowers an entire ecosystem of smartphones, wearables, and connected health solutions with blood pressure monitoring. Our goal is to combine regulatory discipline with scalable innovation. This allows us to make cuffless, calibration-free monitoring accessible not only to patients, providers, and partners worldwide, but also to anyone with undetected hypertension.”
Biozen’s presentation at the AHA Hypertension Scientific Sessions underscores its focus on advancing rigorous clinical validation of its cuffless blood pressure monitoring technology.
About Biozen
Biozen, LLC is a privately held digital health company headquartered in Oklahoma City, Oklahoma, with research and development in Atlanta, Georgia, and software operations in Austin, Texas. Its blood pressure sensing technology, protected by more than 65 granted U.S. and international patents, integrates advanced biosensors with proprietary algorithms to deliver absolute, cuffless blood pressure readings from the fingertip.
Note: The Biozen BP Sensor and BP1000 are investigational devices and are not yet cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.
For more information, visit www.biozen.com.
Media Contact
Ashley Wilson
aw@biozen.com
+1 405-413-5201
SOURCE Biozen, LLC
Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…
Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…
Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…
Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…
Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists…
Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…